Targets › XRCC1
1 program from 1 company in 1 trial: 1 Phase 3; Oncology; next expected readout Dec 2029.
Scaffold protein involved in DNA single-strand break repair by mediating the assembly of DNA break repair protein complexes. Negatively regulates ADP-ribosyltransferase activity of PARP1 during base-excision repair in order to prevent excessive PARP1 activity. (UniProt, P18887)
Open in Phaseline: the race on XRCC1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Cancer Center Hospital East | CAPOXIRI Combination chemotherapy: capecitabine (5-FU prodrug), oxaliplatin (platinum agent), and i | DPYD, TOPO1, XRCC1 | Phase 3 | Locally Advanced Rectal Cancer | Dec 2029 |
Locally Advanced Rectal Cancer (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.